Rheumatologists anticipate that biosimilar etanercept and infliximab will sustain total patient shares of these molecules at the expense of Humira

December 17, 2012 6:56 AM

Decision Resources, one of the research and advisory firms for pharmaceutical and healthcare issues, finds that by year-end 2015, surveyed rheumatologists in the EU5 anticipate that the launches of biosimilar etanercept and infliximab will sustain these molecules’ total patient shares at the expense of Humira in the rheumatoid arthritis (RA) drug market.

The two newer TNF-alpha inhibitors, Cimzia and Simponi will fail to achieve patient shares at the same level of the more established drugs in this class.

The new European Physician & Payer Forum report entitled “How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis?” also finds that Actemra/RoActemra, the most recently launched biologic for the treatment of RA, has gained significant patient share since its approval in Europe in 2009 as survey responses show that it receives similar or greater use than the longer-marketed Orencia and Rituxan/MabThera among respondents’ patients in most EU5 countries.

By year-end 2015, the expected launches of subcutaneous (SC) formulations of Orencia and RoActemra will increase these brands’ current patient shares, and in the case of Orencia, the share of the SC formulation will surpass that of the IV version in all markets under study by year-end 2015.

“Patient shares of the TNF-alpha inhibitors will decline by year-end 2015 despite the availability of discounted biosimilar etanercept and infliximab,” said Decision Resources Analyst Iva Holder, Ph.D. “On the strength of their efficacy data and mode of administration, surveyed rheumatologists estimate that 5 to 14 percent of their patients will be treated with tofacitinib (Xeljanz), with slightly lower estimates for the second-to-market fostamatinib disodium (AstraZeneca).”

The report also finds that, in addition to potential payer restrictions on patient candidates for Pfizer/Takeda’s tofacitinib, physicians’ prescribing practices will also determine tofacitinib’s place in RA treatment algorithms across the EU5. Despite convincing efficacy data in biologic-naive patients (albeit not from head-to-head trials), more surveyed EU5 rheumatologists will use tofacitinib in patients who have failed treatment with one or two biological agents, than in biologic-naive patients within the first two years following the drug’s launch for RA.

The 15 percent of surveyed rheumatologists across the EU5 (mostly in Germany and the United Kingdom) who do not expect to prescribe tofacitinib within the first two years of its launch cited a variety of reasons for this decision. Among them, the need for more convincing data on tofacitinib’s effect on structural damage is highlighted by 39 percent of these respondents, while 37 percent of anticipated non-prescribers expect to encounter difficulties with funding or reimbursement of the drug in their respective countries.


Source: Decision Resources press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!